Background: There is evidence that cognitive remediation (CR) is moderately effective in improving cognitive and functional difficulties in people with schizophrenia. However, there is still a limited understanding of what influence different treatment responses. Aim: To identify moderators influencing CR response in people with schizophrenia. Methods: This systematic review follows PRISMA guidelines. Searches were conducted up to January 2019 on PubMed and PsychInfo to identify randomized controlled trials of CR reporting analyses of moderators of treatment response. All papers were assessed for methodological quality and information on sample size, intervention and control condition, moderators, outcomes, effect of moderator on outcomes and demographic characteristics from each study was extracted and critically summarised. Results: Thirty-six studies were included, considering 2737 participants. Study participants consisted on average of people in their late-thirties, mostly men, with over 10 years of illness. The review identified moderators that could be grouped into five categories: demographics, biological, cognitive and functional, psychological, and illnessrelated characteristics. The assessment of methodological quality showed that many studies had a high risk of bias. Conclusions: There was no high-quality replicated evidence which identifies reliable moderators of CR response. Many moderators were not replicated or presented in single, underpowered studies. Studies also investigated moderators independently despite their potential to overlap (e.g. age and education). Future research should concentrate on evaluating, with sound studies, the role moderators may play in affecting CR treatment response. This information can inform who will benefit most from the therapy and help to improve the benefits of CR.
Introduction
Cognitive impairment is a core feature of schizophrenia with a negative prognostic value for global functioning, social skills, poorer selfcare, and independent living skills (Allott et al., 2011; Bowie et al., 2008; Bowie and Harvey, 2006; Green et al., 2000) . In addition, cognitive deficits reduce the potential benefit of rehabilitation programs, even when high-quality rehabilitation is provided, contributing to higher rates of institutionalization (Bell and Bryson, 2001; McGurk and Meltzer, 2000; Wykes, 1994) . It is for these reasons that cognitive training techniques were developed, in the hope that improving cognition would lead to lasting functional outcome improvements.
Cognitive remediation (CR) is "an intervention targeting cognitive deficit using scientific principles of learning with the ultimate goal of improving functional outcomes" (Cognitive Remediation Experts Workshop, 2012, p. 1) . In the meta-analysis conducted by , CR was found to have a moderate but durable effect on global cognition and functional outcomes. In addition, functioning was improved most when CR was combined with other forms of rehabilitation.
Although CR is an effective approach, there is evidence that as many as one in four participants receiving this intervention will not improve (Murthy et al., 2012; . While many studies have focussed on the evaluation of CR efficacy, only a limited number have considered how individual characteristics, clinical presentation, and other factors may affect treatment response (Fiszdon et al., 2005; Medalia and Richardson, 2005; Twamley et al., 2011; Vita et al., 2013) . Wykes and Spaulding (2011) suggested that these types of studies are important to improve the personalisation agenda of CR even if the results are negative. Systematic evidence on mediators and moderators may allow tailoring therapy according to patients' characteristics in order to maximise its potential benefits.
To date, there is no systematic review of the putative factors which may affect CR response, although some have been suggested in the literature. For instance, a number of studies have suggested that the individuals most likely to benefit from CR are younger (McGurk and Mueser, 2008; , with fewer symptoms and, more severe cognitive difficulties (Pillet et al., 2015; . However, these characteristics have been identified in single studies using underpowered samples. There is limited converging evidence, with some studies suggesting that higher or lower levels of a characteristic (e.g. functioning) may be important in influencing therapy outcomes (Farreny et al., 2016; Twamley et al., 2011) . Further, studies have considered therapy moderators and mediators in relation to different therapy outcomes (e.g. different cognitive domains, functioning, motivation) contributing to the limited consensus in identifying reliable factors that can be used to tailor CR.
Despite the limited evidence, a number of authors (Demily and Franck, 2008; Levaux et al., 2009; Medalia et al., 2018; Silverstein and Wilkniss, 2004) have highlighted the importance of developing a more individualized treatment to improve therapy response. Franck et al. (2013) attempted to personalise CR by adapting training on modules participants received in relation to their initial cognitive assessment (e.g. receiving more training for the most compromised domain). These authors compared the personalised approach to general CR training but found no differences between the two methods suggesting that this personalisation method may not bring about benefits.
While personalisation is increasingly found important, there is no systematic evidence in the literature summarizing relevant findings that may be able to guide future studies. The current review aims to identify potential individual factors at baseline, moderators, that may predict treatment outcomes and that may be used to tailor CR and improve its benefits.
Methods

Research evidence identification
For this review, we followed the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009 ). The review protocol was registered on a public database (e.g. https://www.crd.york.ac.uk/prospero/) on the 27th of February 2018. Searches were conducted up to the 16th of January 2019 on PsycInfo and PubMed databases. We also searched potentially relevant websites including ResearchGate and Mendeley.
In order to identify any additional relevant papers, the reference lists of included studies, relevant and recent reviews (e.g. Wykes and Huddy, 2009; Best and Bowie, 2017; , and relevant articles in this field were also inspected.
Literature search
A broad search string strategy was adopted including the following terms: "exp. schizophrenia" OR "exp. psychosis" OR "exp. schizoaffective disorder" AND "cognitive enhancement" OR "cognitive rehabilitation" OR "cognitive remediation" OR "cognitive training".
Inclusion criteria
Eligible studies:
• Randomized controlled trials. • Assessed the relationship of one or more baseline moderators to CR treatment response. Moderators, according to Baron and Kenny (1986) , are all those factors that identify for whom and under which circumstances treatments have different effects (e.g. age, cognitive profile).
• Included participants over the age of 18 with a diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorder (American Psychiatric Association, 2013), Research Diagnostic Criteria (Spitzer et al., 1978) or International Classification of Diseases (World Health Organization, 1992 ).
• The sample considered had at least 75% of participants with a diagnosis of schizophrenia or schizoaffective disorders.
• The study was in English language. • The CR interventions adopted use principles such as massed practice, errorless learning, and scaffolding to improve cognition and/or social cognition and/or functioning. All modes of administration (computer, pen and paper, individual, group, presence or absence of therapist) were considered.
Exclusion criteria
We excluded all study designs that were not randomized controlled trials (e.g. case studies and opinion papers) or were a combination of randomized and non-randomized controlled trials [e.g. the study conducted by Greenwood et al., 2011] . We also excluded studies where the focus of the intervention was psychoeducation about cognitive difficulties.
Study selection and data extraction
Two authors (BS and DT) independently conducted a screening of all titles and abstracts to identify eligible studies. Disagreements during the selection process were resolved by consultation with a third author (MC).
For all the included studies the following information was extracted:
• sample size for the experimental and control condition; • demographic characteristics including age, gender, years of education, and duration of illness;
• details of the intervention and control condition; • type of moderator considered;
• study primary and secondary outcomes; • reported effect of the moderator on the outcome.
Quality assessment
All included studies were assessed for methodological rigor using the Clinical Trials Assessment Measure (CTAM) (Wykes et al., 2008) . This is a 15-item measure of trial methodology specifically developed for psychological treatment studies. The maximum score is 100 and studies with a CTAM score < 65 are considered at higher risk of bias (Wykes et al., 2008) . All studies were independently rated by two authors (BS and KN) and discrepancies resolved by consultation with a third author (MC). CTAM scores were checked with the study authors and adjusted according to their feedback if provided.
Results
As shown in the PRISMA diagram ( Fig. 1) , the literature search identified thirty-six eligible studies, including 2737 participants. A summary of the studies characteristics is reported in Table 1 .
Sample characteristics
Participants had a mean age of 37.7 years (SD 7.3; range 21.2-48.1), and the majority were men (mean = 66.6%; SD 9.4; range 38.1% -80.5%), with 13.2 years of education (SD 3.8; range 9.7-30.4). Participants had an average illness duration of 12.6 years (SD 7.8; range 1.7-24.5).
Study characteristics
The mean sample size was 76 [(SD 36.9); range 32-175; CR group mean = 41 (SD 18.9); Control group mean = 41.4 (SD 22)]. Most studies were carried out in the United States (N = 23); five studies took place in Spain, four in the United Kingdom and the remaining four in Italy, Australia, Norway, and Switzerland.
Therapy characteristics
Nineteen studies provided CR alone, five combined CR with another active condition (e.g. vocational rehabilitation, social cognitive training) and twelve combined CR with treatment as usual.
Control condition
Twenty-one studies had an active control condition (e.g. computer game, leisure activities), twelve had treatment as usual or waiting list, two had two control conditions (one active and one passive) and another one had an active control condition and a control group including healthy people.
Trial quality
The Clinical Trial Assessment Measure scores for each study are summarised in Table 2 . The mean score was 66.1 (SD 11.7; range 44-90) out of a maximum of 100. Only 21 (53%) studies scored above the cut-off of 65, indicating a low risk of bias (Wykes et al., 2008) . Problems were sample size (33% were too small) with only three studies having adequately calculated power (7.3%), group allocation was not masked (35%), lack of independent randomization (60%), and lack of treatment fidelity assessment (83%).
Moderators affecting treatment response
Twenty studies evaluated at least one moderator; seven assessed two, four evaluated three and, five studies investigated more than three moderators. Taken together, they identified moderators falling into five broad categories: demographic; biological; cognitive and functional; psychological and illness-related aspects. Results for each category are summarised in Table 3 .
Demographic characteristics
A number of papers reported that gender (Farreny et al., 2016; Twamley et al., 2011; Wykes et al., 1999) , education (Farreny et al., Seccomandi, et al. Schizophrenia Research: Cognition 19 (2020) 100160 (continued on next page) B. Seccomandi, et al. Schizophrenia Research: Cognition 19 (2020) 100160 2016; Penades et al., 2016; Twamley et al., 2011) and age (Farreny et al., 2016; Franck et al., 2013; Gomar et al., 2015; Penades et al., 2016; Wykes et al., 1999) were not significant moderators of the effect of CR on therapy outcomes. However, of the studies finding age as a moderator of therapy response, three reported that younger participants benefited more than older in several cognitive domains (Corbera et al., 2017; McGurk et al., 2007; , negative symptoms and functioning . In contrast, four studies found that older participants showed larger improvements in cognition (Thomas et al., 2018; Twamley et al., 2011) , self-esteem ) and, functioning (Dickinson et al., 2010) compared to younger. However, in the study conducted by Dickinson et al. (2010) , age was not found as a moderator of the effect of CR on cognition and symptoms.
The generalisability of the demographic factors considered is subject to limitations. There is limited variability in terms of gender [males were the 75.8% (Wykes et al., 1999) , 65.5% (Farreny et al., 2016) , 68.6% (Twamley et al., 2011) ]. Education was measured using different methods [years of education (Penades et al., 2016; Twamley et al., 2011) , level of education (Farreny et al., 2016) ]. These aspects are likely to affect the quality of the findings and limit the possibility of drawing reliable conclusions. Similarly, in the studies exploring participants' age, each study compared participants from a different age range [under 45 years old and age 45 years old or over, mean age is not reported (McGurk and Mueser, 2008) ; 17-65 years old, mean 36 ; younger than 25-older than 40, mean 33 (Corbera et al., 2017) ; 21-69 years old, mean 45 (Twamley et al., 2011) ; over age 44 vs. under age 45, mean 35.1 (Thomas et al., 2018) ; 18-60 years of age, mean 39.5 (Farreny et al., 2016) ; 18-45 years old, mean 33.5 (Franck et al., 2013) ; age <55 years, mean 36 (Penades et al., 2016) ; 19-64 years old, mean 38.6 (Wykes et al., 1999) ; 21-60 years old, mean 47.7 (Dickinson et al., 2010) ; 20-65 years old, mean 46 (Gomar et al., 2015) ], making it difficult to compare different results. Another limitation is that these studies have a very narrow range to carry out an analysis, for example, in the study conducted by Dickinson et al. (2010) while the age range was 21-60 years old, the majority of participants (within one standard deviation above or below mean) were between 40.3 and 53.5 years limiting how these results will apply to those at the extremes of the distribution. In addition, seven studies analysed age as a continuous variable (Dickinson et al., 2010; Farreny et al., 2016; Franck et al., 2013; Penades et al., 2016; Thomas et al., 2018; Twamley et al., 2011; Wykes et al., 1999) while three studies (Corbera et al., 2017; McGurk and Mueser, 2008; ) considered it as a categorical variable.
Biological features
The studies included highlighted several potential biological moderators including brain structure and genetic variability. Cortical reserve was identified as a moderator although studies used different measures of this concept. Grey matter volume , cortical thickness (Penades et al., 2016) , integrity of the right frontoccipital fasciculus, right corticospinal tract and, bilateral medial lemnisci (Subramaniam et al., 2017) were all found to moderate CR outcomes including social cognition, verbal and non-verbal memory, attention/vigilance and executive function. However, Ramsay et al. (2018) reported that baseline thalamic volume did not moderate improvements in cognition and subcortical volume after CR.
Our searches found two studies investigating genotype as a putative moderator of treatment response. These found differential improvement across variants of the COMT gene in favour of global cognition (Panizzutti et al., 2013) , cognitive flexibility and functioning (Bosia et al., 2007) . By contrast, suggested no significant effect of the COMT genotype on CR response.
Overall the total samples of these brain and genetic studies was small. No study assessed the possibility that the association between Seccomandi, et al. Schizophrenia Research: Cognition 19 (2020) 100160 Table 3 Summary of identified moderators. Seccomandi, et al. Schizophrenia Research: Cognition 19 (2020) 100160 YES Lower baseline symptoms associated with improvements in cognition and left thalamic volume 9 Bark et al., 2003 Fiszdon et al., 2004 Kurtz et al., 2009 Kurtz et al., 2008 Penades et al., 2016 Rodewald et al., 2014 Sanchez et al., 2014 Wykes et al., 1999 Seccomandi, et al. Schizophrenia Research: Cognition 19 (2020) 100160 brain structure and COMT genotype and CR response could have been confounded by the effect of antipsychotic medications, despite the noted influence of drugs on brain structure and dopaminergic system (Bosia et al., 2014) .
Type of features
Cognition and functioning
Our search identified different cognitive and functional aspects as possible moderators. These include cognitive difficulties insight, baseline cognition, IQ, learning potential and baseline functioning. Twamley et al. (2011) found that higher self-reported cognitive problems at baseline was associated with larger improvements in cognition after CR. Conversely, found no difference between people with good or poor cognitive difficulties awareness.
Nine studies evaluated baseline cognition with six finding significant effects and three no effect on CR outcomes (Farreny et al., 2013; McGurk et al., 2009; Ramsay et al., 2018) . However, those that found significant effects reported an association with different outcomes. In four studies higher baseline cognition was associated with larger improvement in functioning (Kurtz et al., 2009; Kurtz et al., 2008) , negative symptoms (Farreny et al., 2016) and cognition (Penades et al., 2016) after CR. Conversely, two studies reported that lower initial cognition was associated with larger cognitive improvements (Rodewald et al., 2014; Twamley et al., 2011) and functioning (Twamley et al., 2011) after CR.
Of the three studies investigating IQ, one found lower IQ was related to smaller gains (Fiszdon et al., 2006) , one that higher premorbid IQ was related to fewer gains (Franck et al., 2013) and one reported no difference (Twamley et al., 2011) .
Our search identified only one study evaluating learning potential which predicted improvement in verbal and visual memory (Davidson et al., 2016) .
Of the six studies investigating baseline functioning, three noted that better functioning was associated with a larger improvement in functioning (Farreny et al., 2016; Kurtz et al., 2008) higher competitive employment and lower unemployment (Evensen et al., 2017) . In contrast, Twamley et al. (2011) found that people with lower function showed larger gains; with this finding confirmed by Bell et al. (2008) . In a more recent study by Bell et al. (2014) , people with poor community function receiving CR plus supported employment program had better competitive employment rates and worked more hours than people who only received a supported employment program alone. However, for participants with higher community function at entry to the study CR conferred no extra benefit (Bell et al., 2014) .
The main limitation of this set of studies was the relatively small sample sizes which meant that although they found a significant, the effect size reliability is low. Outcomes were measured with different tests, making the comparison complicated (e.g. in baseline cognition studies Kurtz et al. (2008) measured verbal learning and memory with the California Verbal Learning Test, whereas Twamley et al. (2011) used Hopkins Verbal Learning Test; in functioning, Farreny et al. (2016) used Life Skills Profile, Kurtz et al. (2008) the University of California San Diego Performance-based Skills Assessment and, Twamley et al. (2011) Quality of Life Interview; in IQ research, Fiszdon et al. (2006) used the Information subtest of the Wechsler Adult Intelligence Scale, Franck et al. (2013) French National Adult Reading Test).
Psychological features
Our search identified two psychological factors investigated as possible moderators: motivation, and self-esteem. For motivation, Fisher et al. (2015) reported that an individual's baseline motivation (assessed by anticipatory and consummatory of pleasure) was associated with improvements in global cognition and verbal memory after therapy. But, Rodewald et al. (2014) , found that motivation (considered both as negative symptoms and intrinsic motivation) had no effect on improvement in problem-solving ability.
Two studies evaluated self-esteem with one showing that higher self-esteem at baseline was associated with better competitive employment and lower unemployment (Evensen et al., 2017) and the other found no influence on cognitive gains (Bellucci et al., 2003) .
It is, however, important to highlight that an accurate comparison between motivation studies is difficult because each study considered a different facet of motivation and measuring motivation is complex. The studies conducted by Bellucci et al. (2003) and Evensen et al. (2017) also have a modest sample size and an active control group (vocational rehabilitation services) that might have influenced the results.
Illness-related features
We identified six illness-related factors as possible moderators: symptoms, medication, diagnosis, comorbid disorders, duration of illness and number of hospitalisations. In terms of symptoms, some studies found that higher baseline symptoms severity was associated to larger improvements in functioning (Farreny et al., 2013; Twamley et al., 2011) and cognition (Farreny et al., 2016; Twamley et al., 2011) . But others reported that lower baseline symptoms severity was related to better functioning (Farreny et al., 2016) , negative symptoms (Farreny et al., 2016) , cognition and subcortical volume preservation (Ramsay et al., 2018) after therapy. Another nine studies (Bark et al., 2003; Fiszdon et al., 2004; Kurtz et al., 2009; Kurtz et al., 2008; Penades et al., 2016; Rodewald et al., 2014; Sanchez et al., 2014; Thomas et al., 2018; Wykes et al., 1999) , found no association between baseline symptoms profile and CR outcomes.
Again, these studies had limitations: used different PANSS factor models and participants in different studies had different levels of symptoms. For example, Twamley et al. (2011) used the PANSS threefactor structure from Kay et al. (1987) but considered only the Positive (mean 16.0) and Negative dimensions (mean 15.6). Ramsay et al. (2018) used the same factor structure but considered Positive (mean 12.65), Negative (mean 17.18) and General symptoms (mean 33.32) scores. Farreny et al. (2013) used both PANSS three-and five-factor (Wallwork et al., 2012) , analysing only Negative symptoms (mean 2.7). Farreny et al. (2016) , instead, considered a 5-factor structure by Wallwork et al. (2012) ; Positive (mean 6.8), Negative (mean 16), Disorganized (mean 8.4) Depressed (mean 6.8) and Excited (mean 5.8).
There were also inconsistencies in how medication influenced therapy outcomes with two studies reporting that those on a lower dose of antipsychotic medication were more likely to complete the therapy (Twamley et al., 2011) and show improvement on problem-solving (Rodewald et al., 2014) . One study, however, showed the opposite with higher medication levels being associated with improvements in verbal learning (Thomas et al., 2018) . Gomar et al. (2015) did not find that antipsychotic dose moderated CR outcomes. Vinogradov et al. (2009) found that serum anticholinergic activity, an index of individual's anticholinergic burden, contributed by the cumulative effect of drugs and their metabolites, was associated with poorer CR response. A study by Wykes et al. (1999) showed that people who received atypical antipsychotic medications showed larger effects on cognition after CR compared to those who had been prescribed typical antipsychotics, but this difference was not maintained at follow-up. In a further study, Wykes et al. (2007) reported that people who received either clozapine or typical antipsychotic achieved better results after therapy in comparison with those who received other atypical medications. Finally, three studies showed that medication levels before therapy did not predict CR response for cognition, functioning or symptoms improvements (Farreny et al., 2016; Penades et al., 2016; Sanchez et al., 2014) . It is, however, important to highlight that a comparison between these studies is difficult because each study used different medications (e.g. first-and second-generation of antipsychotics).
Diagnosis and additional comorbid disorders are other illness-related aspects identified as possible moderators. We found only one study (Twamley et al., 2011) suggesting that participants with schizoaffective disorder reported greater CR-associated improvement, in subjective quality of life, compared with those with a diagnosis of schizophrenia. However, Lewandowski et al. (2011) did not find the diagnosis as a moderator. McGurk et al. (2009) , comorbid substance abuse was related to worse employment outcomes, after CR plus vocational rehabilitation and vocational rehabilitation alone, while the presence of a physical comorbid condition (e.g. metabolic deficits) was not associated with work outcomes.
The effects of illness duration on CR outcomes were mixed: with superior CR benefits reported for individuals with shorter illnesses length reported by Corbera et al. (2017) but no associations found in four other studies (Farreny et al., 2016; Penades et al., 2016; Thomas et al., 2018; Twamley et al., 2011) . Penades et al. (2016) reported that the number of hospitalisations (mean 1.76) had no effects on CR outcomes. However, there is large variability in participants' illness duration across these studies making, again, comparisons difficult with average illness length ranging from 9.3 to 20.5 years. There were also differences in the way these studies analysed illness duration with the only study that found an effect considered it as categorical, unlike all other studies that considered illness duration as continuous and found negative results.
Discussion
The aim of this study was to review the literature to identify moderators of CR treatment response which can be used to understand why different participants achieve different outcome after CR.
This review identified 18 moderators considered to have an effect on CR; however, we found no high-quality replicated evidence for any of these. The majority of the studies reviewed lacked adequate power to conduct moderation analysis and half of the studies had poor methodological quality are considered at high risk of bias. The variability in the CR approaches and control groups considered might have also played a role in the lack of findings convergence. Studies also measured the same outcomes in different ways, particularly cognition but also functioning, with measures spanning from capacity to role functioning. Further, the studies included in this review considered a large number of moderators for a large number of outcomes. This created a vast amount of research questions which may make the current set of results at risk of reporting false positives. In addition, different individual potential predictors were investigated independently despite the possibility for a combined effect on CR (e.g. learning potential, education, and age).
To move the personalisation agenda of CR forward evidence on moderators needs to be stronger, replicated and based on appropriately powered research. In the section below, we have highlighted some research implications for the field to consider.
Research implications
While it is well known that positive findings are more likely to be published (Mlinarić et al., 2017) , it is recognised that negative findings play an important role in shaping knowledge advancement. The majority of the studies we reviewed reported positive results. This may be because positive results are more often reported and mentioned in papers. However, it is likely that negative results were found as often but not reported contributing to a "skewed view" of the moderators' landscape. Future research should consider more routine reporting of negative findings.
As the results of this review show, there is no strong evidence for any of the moderators identified. While this is likely to be due to the lack of rigorous studies, it also shows that the field has, so far, focussed on exploratory studies to identify potential moderators. While this is a necessary first step, what the field needs now is replication and evidence consolidation. This will require large datasets and clear hypothesis-driven studies to test specific moderators and estimate more precisely their effect size on outcomes of interest.
It is also important to consider the mechanisms by which a moderator may act on therapy. Like other psychological therapies, CR relies on factors implicated in learning such as age, IQ, learning potential, motivation, self-esteem, and working alliance. These are hypothesis-based moderators and can be investigated based on a coherent theoretical framework. For example, there is evidence that people with schizophrenia have low self-esteem and that this has a negative impact on engagement and may have a detrimental effect on outcomes Huddy et al., 2012) . Self-esteem also affects the perception that people with schizophrenia have about their cognitive difficulties (Cella et al., 2014) . Moderators linked to hypothesised mechanisms of action may be more likely to show consistent trends and be used to understand mechanisms of CR effectively.
Research showed that people with schizophrenia have unique type and severity profiles of cognitive impairment (Silverstein, 2000) . As CR targets cognitive difficulties, it is unclear whether different profiles of cognitive impairment would require different therapies regimes. Using an analogy from medication prescribing, one may hypothesise that more severe impairment may require higher therapy intensity (e.g. dose) or frequency. However, as psychological therapy, CR may respond to a different type of personalisation not necessarily to do with therapy dose and frequency but with ingredient types or dose. It may be that adapting or calibrating training to a particular profile of cognitive impairment may help to improve treatment response. A recent attempt at personalisation in this sense has not proven to be successful (Franck et al., 2013) but personalisation in this study was done only on one cognitive domain (e.g. executive function). It may be that training programs need to consider personalisation on multiple cognitive domains.
As research on personalisation progresses, it is also important to consider what outcome is the personalisation aiming to improve. A recent study compared different CR training methods targeting executive and perceptual processes (Best et al., 2019) . Personalisation for perceptual processes programs may be very different to executive programs and research in these two areas may reflect different priorities. One, more research-based and more interested in the underlying mechanism of CR, while the other more clinical and focussed on improving outcomes for people with schizophrenia.
Limitations
The studies included have several limitations that can be grouped in main areas:
(i) Generalisability: While the results in this study are based on a sample's characteristics which reflect people with schizophrenia presenting to clinical services, the generalisability of these findings may be subject to limitations. For instance, the majority of the included studies consider samples with a high proportion of male participants and with a restricted range of age (21.2-48.1 years old). While these are likely to be the most common demographics associated with participants taking part in CR studies, it may be difficult to generalise the findings to female and younger or older people. In addition, we included only English-language publications and the majority of the studies considered took place in United States. These aspects may limit the generalisability of our results to other countries and cultures. (ii) Methodological quality: The majority of the studies considered lacked independent randomization and/or treatment fidelity assessment. This is a potential source of bias as it may mean that assessor blinding was not rigorously implemented and that participants may have received treatment of variable quality within the same study. Caution should be used in drawing firm conclusions from these studies." (iii) Measure heterogeneity: Studies measured the same outcomes using different methods tools, making the comparison and an overall conclusion about the effect of moderators difficult. Future research would benefit for using standardized assessments and well-normed neurocognitive, functional, and symptoms batteries.
(iv) Ratio for study selection: This review only considered studies that mentioned the assessment of moderators in the abstract. This search strategy might therefore have missed relevant papers where the moderators were assessed but not reported. These moderation analyses were likely to be negative. In addition, it was difficult to ascertain if any moderators were hypothesis-driven or opportunistic as most studies did not have pre-registered analysis plans. (v) Heterogeneity of CR therapy and type of control: The results heterogeneity found in this review may be due to differences in the CR intervention used. These include differences in intervention length, mode of administration (paper and pencil, computer, individual, group), focus of training (single versus multi-domain as well as drill-and-practice versus drill plus strategy training) and whether the intervention is administered as a stand-alone or part of a broader rehabilitation program.
There is also heterogeneity in the control groups with some studies having active control groups (e.g. computer games), others a passive control condition (e.g. treatment as usual), and some studies both. For instance, Farreny et al. (2016) used a CR strategy-based training focus on executive function and metacognition, in a group format, with a duration of 16 weeks and consisting of 32 sessions and did not found age as a moderator of CR benefits. On the other hand, Wykes and Huddy (2009) , used CR plus treatment-as-usual, 3 days per week until 40 sessions were completed, in an individual format, and with treatment-as-usual as control group and found age as a moderator of treatment response.
In the future, it might be useful to conduct studies using large datasets produced by aggregating data from existing trial to reduce the effect of different therapy programs and control groups. This is what the National Institute for Mental Health is aiming to do by developing the Database of Cognitive Training and Remediation Studies (DoCTRS) (for example of DoCTRS database use . These data would allow to test mechanisms and moderators of CR with an adequate statistical power and limit the influence of individual studies procedures and control groups on CR outcomes.
Conclusion
Even though there is evidence of substantial individual differences in response to CR (Murthy et al., 2012; , we still have a limited understanding of what causes variability in CR response. This review highlighted five categories of moderators that might influence CR response. We did not find strong evidence in support of any of them. Many significant effects were in opposite directions and most studies were small. The importance of this work is in summarizing the evidence so far accumulated in the field and suggesting moderators to be investigated in future studies. A recommendation is for appropriately powered and hypothesis driven moderation studies. While this may be difficult to achieve in one study, merging data from existing trials may provide the solution. Achieving clear evidence on the role of moderators in CR and using this information for understanding who will benefit more from the therapy relies largely on future studies adhering to good quality methodology and more shared efforts to identify key factors to investigate.
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